index - Epidemiology in dermatology and evaluation of therapeutics

DOCUMENTS

95

 

NOTICES

156

 

 

MOTS CLES

Cancer Drug reaction Anti-Bacterial Agents Management Azathioprine Biomarkers Bacterial Antimicrobial Stewardship Psoriatic arthritis Biologics Biological therapy Antimicrobials Systematic review Intensive care Graft-versus-host disease Sipuleucel-T Antibiotic misuse Abus d'antibiotiques Anti-TNF Arrhythmia Cardiomyopathy Ankylosing Ankylosing spondylitis ASDAS Biologic therapy Psoriasis Arthritis Antimicrobial resistance Pharmacovigilance COVID-19 Addiction Etanercept Adalimumab Antibiotic resistance Immune checkpoint inhibitors Anti-HCV Direct Acting Antivirals DAA Pregnancy Prostate cancer Cardiotoxicity Anticancer drugs Antimicrobiens Accelerometer Vigibase® Burden Primary adrenal insufficiency Angiotensin receptor blockers Spondyloarthritis Axial spondyloarthritis Stability Endocrine toxicity Albinism Biologic Dermatology Atopic dermatitis Alitretinoin Auto-Diagnostic Biosimilar Pharmaceuticals Antibiotics Glucocorticoids Meta-Analysis Immunotherapy Placebo Adverse side effects Infliximab Pharmacoepidemiology Atrial fibrillation Epidemiology Aging Auto-immune hepatitis Angiotensin-converting enzyme inhibitors ArtThese Biologic drug Amyloidosis Ustekinumab Pharmaco-Épidémiologie Quality of life Méta-Analyse Autoimmune diseases Access to care Sacroiliitis Biological Therapy Beta-lactam antibiotics Alcohol Apremilast Acute Myeloid Leukaemia AML Autoimmunity Spondylitis Drug survival Cardio-oncology Adolescent Apre-milast Immune-related adverse events Network meta-analysis Ethics Anxiety Treatment Biomédicaments BTK protein Bacterial rhinosinusitis Anxiété

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS